Immunoprecise Antibodies
About: ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.
Employees: 101
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
88% more capital invested
Capital invested by funds: $786K [Q4 2024] → $1.48M (+$694K) [Q1 2025]
26% more funds holding
Funds holding: 19 [Q4 2024] → 24 (+5) [Q1 2025]
2.45% more ownership
Funds ownership: 6.14% [Q4 2024] → 8.59% (+2.45%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth | 920%upside $5 | Buy Reiterated | 11 Apr 2025 |
Benchmark Robert Wasserman | 512%upside $3 | Speculative Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion









